 |
PDBsum entry 1n4h
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hormone/growth factor
|
PDB id
|
|
|
|
1n4h
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nat Struct Biol
10:820-825
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta.
|
|
C.Stehlin-Gaon,
D.Willmann,
D.Zeyer,
S.Sanglier,
A.Van Dorsselaer,
J.P.Renaud,
D.Moras,
R.Schüle.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Retinoids regulate gene expression through binding to the nuclear retinoic acid
receptors (RARs) and retinoid X receptors (RXRs). In contrast, no ligands for
the retinoic acid receptor-related orphan receptors beta and gamma (ROR beta and
gamma) have been identified, yet structural data and structure-function analyses
indicate that ROR beta is a ligand-regulated nuclear receptor. Using
nondenaturing mass spectrometry and scintillation proximity assays we found that
all-trans retinoic acid (ATRA) and several retinoids bind to the ROR beta
ligand-binding domain (LBD). The crystal structures of the complex with ATRA and
with the synthetic analog ALRT 1550 reveal the binding modes of these ligands.
ATRA and related retinoids inhibit ROR beta but not ROR alpha transcriptional
activity suggesting that high-affinity, subtype-specific ligands could be
designed for the identification of ROR beta target genes. Our results identify
ROR beta as a retinoid-regulated nuclear receptor, providing a novel pathway for
retinoid action.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Nondenaturing ESI-MS analysis of ligand binding to ROR
.
(a) ROR -stearate
complex (ROR -STE):
before addition of any ligand, 90%
of the detected species correspond to the ROR -STE
complex and 10% are related to unliganded ROR .
(b) ROR -ATRA
complex: after addition of 2.5 molar equivalents of ATRA
(molecular mass = 300.4 Da), the only detected species
corresponds to the ROR -ATRA
complex. Neither unliganded ROR nor
the ROR -STE
complex is present in the ESI mass spectrum. (c) ROR -ALRT
1550 complex (ROR -ALRT):
after addition of 2.5 molar equivalents of ALRT (molecular mass
= 340.5 Da), the only detected species corresponds to the ROR
-ALRT
complex. Neither unliganded ROR nor
the ROR -STE
complex is present in the ESI mass spectrum. The ESI-MS measured
masses for the different complexes are: 31,034.5 0.5
Da for ROR ,
31,321.4 0.9
Da for ROR -STE,
31,334.6 1.3
Da for ROR -ATRA
and 31,373.9 0.8
Da for ROR -ALRT.
Asterisk represents ROR without
the His[6]-tag; G, gluconoylation of the His[6]-tag; PG,
phosphogluconoylation of the His[6]-tag28.
|
 |
Figure 2.
Figure 2. Crystal structures of the ROR LBD
in complex with ATRA and ALRT. (a) Stereo view of the
backbone superposition of the structures of the ROR LBD
(yellow) in complex with stearate (orange) and the SRC-1 peptide
(red) (PDB entry 1K4W) and of the ROR LBD
(green) in complex with ATRA (dark blue) and the SRC-1 peptide.
(b) Electron density omit maps of the bound ligands. The maps
were calculated at 2.1 Å for ATRA (left) and 1.5 Å for ALRT
(right). Contour levels are 2.0 and
2.5 ,
respectively; labels refer to the canonical helix numbering. (c)
Anchoring of the carboxylate of ATRA in two different LBDs.
Left, ATRA (yellow) and stearate (orange) in ROR ;
the superposition was made on the protein atoms. Right, ATRA in
hRAR (PDB
entry 2LBD). In ROR ,
ATRA forms two water mediated hydrogen bonds to Arg306 and
Arg309 whereas in RAR it forms one direct hydrogen bond to
Arg278. (d) Stereo view of the superposition of stearate
(orange), ATRA (yellow) and ALRT (green) in the ROR ligand-binding
pocket. The protein atoms follow the standard color code.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2003,
10,
820-825)
copyright 2003.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Wilkinson,
T.Hallis,
S.Hermanson,
and
K.Bi
(2011).
Development and validation of a cell-based assay for the nuclear receptor retinoid-related orphan receptor gamma.
|
| |
Assay Drug Dev Technol,
9,
125-135.
|
 |
|
|
|
|
 |
G.S.Lee,
X.Liao,
H.Shimizu,
and
M.D.Collins
(2010).
Genetic and pathologic aspects of retinoic acid-induced limb malformations in the mouse.
|
| |
Birth Defects Res A Clin Mol Teratol,
88,
863-882.
|
 |
|
|
|
|
 |
L.A.Solt,
P.R.Griffin,
and
T.P.Burris
(2010).
Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics.
|
| |
Curr Opin Lipidol,
21,
204-211.
|
 |
|
|
|
|
 |
L.Jin,
and
Y.Li
(2010).
Structural and functional insights into nuclear receptor signaling.
|
| |
Adv Drug Deliv Rev,
62,
1218-1226.
|
 |
|
|
|
|
 |
L.Xiao,
X.Xie,
and
Y.Zhai
(2010).
Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism.
|
| |
Adv Drug Deliv Rev,
62,
1316-1321.
|
 |
|
|
|
|
 |
M.Theodosiou,
V.Laudet,
and
M.Schubert
(2010).
From carrot to clinic: an overview of the retinoic acid signaling pathway.
|
| |
Cell Mol Life Sci,
67,
1423-1445.
|
 |
|
|
|
|
 |
S.Mukherjee,
and
S.Mani
(2010).
Orphan nuclear receptors as targets for drug development.
|
| |
Pharm Res,
27,
1439-1468.
|
 |
|
|
|
|
 |
A.M.Jetten
(2009).
Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism.
|
| |
Nucl Recept Signal,
7,
e003.
|
 |
|
|
|
|
 |
Y.Chen,
S.Coulter,
A.M.Jetten,
and
J.A.Goldstein
(2009).
Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene.
|
| |
J Pharmacol Exp Ther,
329,
192-201.
|
 |
|
|
|
|
 |
G.M.Waitt,
R.Xu,
G.B.Wisely,
and
J.D.Williams
(2008).
Automated in-line gel filtration for native state mass spectrometry.
|
| |
J Am Soc Mass Spectrom,
19,
239-245.
|
 |
|
|
|
|
 |
T.Wada,
H.S.Kang,
A.M.Jetten,
and
W.Xie
(2008).
The emerging role of nuclear receptor RORalpha and its crosstalk with LXR in xeno- and endobiotic gene regulation.
|
| |
Exp Biol Med (Maywood),
233,
1191-1201.
|
 |
|
|
|
|
 |
C.Bovet,
A.Wortmann,
S.Eiler,
F.Granger,
M.Ruff,
B.Gerrits,
D.Moras,
and
R.Zenobi
(2007).
Estrogen receptor-ligand complexes measured by chip-based nanoelectrospray mass spectrometry: an approach for the screening of endocrine disruptors.
|
| |
Protein Sci,
16,
938-946.
|
 |
|
|
|
|
 |
G.A.LeBlanc
(2007).
Crustacean endocrine toxicology: a review.
|
| |
Ecotoxicology,
16,
61-81.
|
 |
|
|
|
|
 |
L.Altucci,
M.D.Leibowitz,
K.M.Ogilvie,
A.R.de Lera,
and
H.Gronemeyer
(2007).
RAR and RXR modulation in cancer and metabolic disease.
|
| |
Nat Rev Drug Discov,
6,
793-810.
|
 |
|
|
|
|
 |
M.V.Flores,
C.Hall,
A.Jury,
K.Crosier,
and
P.Crosier
(2007).
The zebrafish retinoid-related orphan receptor (ror) gene family.
|
| |
Gene Expr Patterns,
7,
535-543.
|
 |
|
|
|
|
 |
Y.Shi
(2007).
Orphan nuclear receptors in drug discovery.
|
| |
Drug Discov Today,
12,
440-445.
|
 |
|
|
|
|
 |
A.Geerlof,
J.Brown,
B.Coutard,
M.P.Egloff,
F.J.Enguita,
M.J.Fogg,
R.J.Gilbert,
M.R.Groves,
A.Haouz,
J.E.Nettleship,
P.Nordlund,
R.J.Owens,
M.Ruff,
S.Sainsbury,
D.I.Svergun,
and
M.Wilmanns
(2006).
The impact of protein characterization in structural proteomics.
|
| |
Acta Crystallogr D Biol Crystallogr,
62,
1125-1136.
|
 |
|
|
|
|
 |
A.M.Jetten,
and
J.H.Joo
(2006).
Retinoid-related Orphan Receptors (RORs): Roles in Cellular Differentiation and Development.
|
| |
Adv Dev Biol,
16,
313-355.
|
 |
|
|
|
|
 |
G.Jones,
D.Jones,
P.Teal,
A.Sapa,
and
M.Wozniak
(2006).
The retinoid-X receptor ortholog, ultraspiracle, binds with nanomolar affinity to an endogenous morphogenetic ligand.
|
| |
FEBS J,
273,
4983-4996.
|
 |
|
|
|
|
 |
S.N.Ramakrishnan,
and
G.E.Muscat
(2006).
The orphan Rev-erb nuclear receptors: a link between metabolism, circadian rhythm and inflammation?
|
| |
Nucl Recept Signal,
4,
e009.
|
 |
|
|
|
|
 |
T.Kilic,
S.Sanglier,
A.Van Dorsselaer,
and
D.Suck
(2006).
Oligomerization behavior of the archaeal Sm2-type protein from Archaeoglobus fulgidus.
|
| |
Protein Sci,
15,
2310-2317.
|
 |
|
|
|
|
 |
F.Molnár,
M.Matilainen,
and
C.Carlberg
(2005).
Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators.
|
| |
J Biol Chem,
280,
26543-26556.
|
 |
|
|
|
|
 |
J.Lengqvist,
A.Mata de Urquiza,
T.Perlmann,
J.Sjövall,
and
W.J.Griffiths
(2005).
Specificity of receptor-ligand interactions and their effect on dimerisation as observed by electrospray mass spectrometry: bile acids form stable adducts to the RXRalpha.
|
| |
J Mass Spectrom,
40,
1448-1461.
|
 |
|
|
|
|
 |
K.King-Jones,
and
C.S.Thummel
(2005).
Nuclear receptors--a perspective from Drosophila.
|
| |
Nat Rev Genet,
6,
311-323.
|
 |
|
|
|
|
 |
P.Du,
P.Loulakis,
Z.Xie,
S.P.Simons,
and
K.F.Geoghegan
(2005).
Tandem mass spectrometry of multiply phosphorylated forms of a 'histidine-tag' derived from a recombinant protein kinase expressed in bacteria.
|
| |
Rapid Commun Mass Spectrom,
19,
547-551.
|
 |
|
|
|
|
 |
W.Wang,
C.Zhang,
A.Marimuthu,
H.I.Krupka,
M.Tabrizizad,
R.Shelloe,
U.Mehra,
K.Eng,
H.Nguyen,
C.Settachatgul,
B.Powell,
M.V.Milburn,
and
B.L.West
(2005).
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.
|
| |
Proc Natl Acad Sci U S A,
102,
7505-7510.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.R.Broussard,
M.M.Lozano,
and
J.P.Dudley
(2004).
Rorgamma (Rorc) is a common integration site in type B leukemogenic virus-induced T-cell lymphomas.
|
| |
J Virol,
78,
4943-4946.
|
 |
|
|
|
|
 |
G.Benoit,
M.Malewicz,
and
T.Perlmann
(2004).
Digging deep into the pockets of orphan nuclear receptors: insights from structural studies.
|
| |
Trends Cell Biol,
14,
369-376.
|
 |
|
|
|
|
 |
H.Gronemeyer,
J.A.Gustafsson,
and
V.Laudet
(2004).
Principles for modulation of the nuclear receptor superfamily.
|
| |
Nat Rev Drug Discov,
3,
950-964.
|
 |
|
|
|
|
 |
J.Kallen,
J.M.Schlaeppi,
F.Bitsch,
I.Delhon,
and
B.Fournier
(2004).
Crystal structure of the human RORalpha Ligand binding domain in complex with cholesterol sulfate at 2.2 A.
|
| |
J Biol Chem,
279,
14033-14038.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Q.Xu,
J.Lucio-Cazana,
M.Kitamura,
X.Ruan,
L.G.Fine,
and
J.T.Norman
(2004).
Retinoids in nephrology: promises and pitfalls.
|
| |
Kidney Int,
66,
2119-2131.
|
 |
|
|
|
|
 |
S.Sanglier,
W.Bourguet,
P.Germain,
V.Chavant,
D.Moras,
H.Gronemeyer,
N.Potier,
and
A.Van Dorsselaer
(2004).
Monitoring ligand-mediated nuclear receptor-coregulator interactions by noncovalent mass spectrometry.
|
| |
Eur J Biochem,
271,
4958-4967.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |